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Abstract
Background: The pathophysiological origin of juvenile idiopathic arthritis (JIA) is largely unknown. However,
individuals with presumably pathogenic mutations in FAMIN have been reported, associating this gene with a rare
subtype of this disorder. FAMIN, that is formerly also referred to as LACC1 or C13orf31, has recently been shown to
play a crucial role in immune-metabolic functions and is involved in regulation of inflammasome activation and
promotion of ROS production.
Case presentation: We describe two siblings with severe familial forms of juvenile arthritis in which whole-exome-
sequencing revealed a novel homozygous frameshift mutation (NM_153218.2:c.827delC¸. p.(T276fs*2) in FAMIN.
Conclusions: The observation of a new deleterious mutation adds further evidence that pathogenic mutations in
FAMIN are causal for a monogenic form of JIA. Furthermore the associated phenotype is not restricted to systemic
JIA, but can also be found in other forms of familial juvenile arthritis.
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Background
Despite intensive analyses, the precise mechanisms lead-
ing to the phenotype of systemic juvenile idiopathic
arthritis (sJIA) are still unknown (reviewed by [1]).
Current understanding favors a model in which deregu-
lation of innate immune mechanisms causes an upregu-
lation of various soluble mediators, e.g. IL-1β [2], IL-18
[3], IL-6 [4] and the S100 molecules [5] and orchestrates
a proinflammatory response reaction. Furthermore, an
association of polymorphisms within the IL1 and IL1R
cluster genes [6, 7], the macrophages migration inhibitor
factor (MIF) and the IL10 cytokine cluster [8] has previ-
ously been described. Furthermore, a current genome
wide association study (GWAS) identified the MHC
locus as a bona fide susceptibility locus for the pheno-
type of sJIA [9].
In a previous report familial cases with sJIA have
been linked to the gene FAMIN, (‘fatty acid metabol-
ism – immunity nexus’, formerly also referred to as
LACC1 or C13orf31). Wakil et al. identified the
homozygous missense mutation, p.Cys284Arg, in af-
fected individuals from consanguineous Saudi Arabian
families [10]. Furthermore, Arostegui, et al. reported
a frame-shift mutation, p.Cys43Tyrfs*6, in three sib-
lings from a consanguineous Moroccan family with
severe highly inflammatory rheumatoid factor-negative
polyarticular JIA [11].
These clinical reports coincide with a very recently
published study that describe FAMIN as central regu-
lator of endogenous fatty acid synthesis and their
mitochondrial oxidation in macrophages [12]. In this
respect, intact FAMIN is crucial in the production of
inflammasome-mediated IL-1β as well as reactive
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oxygen species (ROS). FAMIN mutations are primarily de-
scribed as having a loss-of-function effect on metabolic
cell function and subsequent immunological response.
Nevertheless, high dosages of lipopolysaccharides
(LPS) induced catastrophic activation of IL-1β in
FAMIN−/− mice, indicating that the profoundly im-
paired ‘energetic reserves’ might predipose these cells
towards a pyroptotic, pro-death response.
We here present two siblings with severe forms of ju-
venile arthritis both harbouring a novel homozygous
frameshift mutation within FAMIN. One sibling add-
itionally developed precursor-B cell acute lymphoblastic
leukemia (ALL). This report extends the phenotype of
monogenic juvenile arthritis and adds evidence for the
causative role of FAMIN in these cases.
Case presentation
The consanguineous family originates from Lebanon
(Fig. 1). The two affected girls as well as the two healthy
siblings were born in Germany. Neither the parents nor
the other siblings ever showed evidence of arthritis, sys-
temic inflammation or recurrent infections.
At the age of 16 months the older child (II-3) devel-
oped simultaneously severe polyarthritis of wrists, knees
and ankles, lymphadenopathy, extreme sensitivity to
body contact, quotidian fever and remarkably elevated
inflammatory markers (CRP 121 mg/l, leukocytes 18/nl).
No serositis or exanthema was noticed. After intensive ex-
clusion of other causes including bone marrow aspiration,
systemic juvenile idiopathic arthritis was diagnosed ac-
cording to the International League of Associations for
Rheumatology (ILAR)-criteria.
The treatment consisted of repeated intraarticular ster-
oid injections (shoulders, elbows, hands, hips, knees and
ankles), non-steroidal anti-inflammatory drugs, high
doses of corticosteroids (2 mg/kg) and methotrexate.
Etanercept and Anakinra did not lead to a sufficient
disease control. Finally, clinical remission was achieved
3,5 years after introduction of tocilizumab and metho-
trexate in addition to low dose steroids (0,2 mg/kg) and
non-steroidal anti-inflammatory drugs.
At the age of six, the girl developed thrombocytopenia
(56/nl) and precursor-B cell ALL was diagnosed. Over
seven months the girl was treated with intensive chemo-
therapy according to the AIEOP-BFM ALL 2009 protocol.
During this time she repeatedly suffered from severe flares
of arthritis even shortly after chemotherapy (e.g. cyclo-
phosphamide 1 g/m2), which resolved spontaneously.
At the age of eight, ALL relapse (bone marrow and
central nervous system) was diagnosed. Second remis-
sion was achieved by chemotherapy according to the
ALL-REZ BFM 2002 protocol. Allogeneic bone marrow
transplantation from an unrelated 9/10 HLA-identical
donor was performed after total body irradiation (12Gy
+ 6 Gy CNS boost) and high-dose chemotherapy. Post-
transplant course was complicated by acute grade IV
graft-versus-host disease of liver and skin. With respect
to the ALL and the juvenile arthritis the girl is in con-
tinuous remission without immunosuppressive therapy
since 24 months after bone marrow transplantation.
The seven-year-old female sister of the same family
(II- 3) developed first manifestations of arthritis (knee
and ankles) at the age of 15 months, which was initially
classified as oligoarticular juvenile idiopathic arthritis
and treated with intraarticular steroidinstillation and
nonsteroidal anti-inflammatory drugs.
Eight months later the juvenile idiopathic arthritis
flared up with a symmetric polyarthritis (shoulder, el-
bows, knees, ankles, wrists) and thus reclassified as
extended oligoarticular JIA. Unusually high inflamma-
tory makers (e.g. CRP 221 mg/l, leucocytes 18/nl)
were noticed, but fever, rash, organomegaly or lymph-
adenopathy was not present. Treatment with metho-
trexate and systemic steroids (1 mg/kg) was started.
Due to uncontrolled systemic inflammation adalimu-
mab in combination with hydroxychloroquine was
introduced and sufficient control of the inflammation
was achieved.
In both children whole-exome-sequencing revealed
the homozygous one base pair deletion in FAMIN
NM_153218.2:c.827delC. The mutation results in a
frameshift and a premature stop codon, p.(Thr276fs*2).
Both parents are heterozygous carriers of the deletion
and the two unaffected children showed the wildtype of
the gene.
Conclusion
In this report we describe the novel homozygous frame-
shift mutation, p.Thr276fs*2, in FAMIN. The observation
that a frameshift mutation leads to a similar juvenile arth-
ritis phenotype comparable to the previously described
Fig. 1 Pedigree
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mutations strongly supports the significance of these gene
variants in the development of juvenile arthritis. Our cases
demonstrate, that FAMIN mutations can also be found in
extended oligoarticular juvenile arthritis associated with
systemic inflammation.
Interestingly, all case reports with deleterious muta-
tions in FAMIN have so far been from families of Arab
ethnicity. However, this might simply be due to the fact,
that the identification of pathogenic mutations is facili-
tated in highly consanguineous families. It is noteworthy,
that none of the reported pathogenic mutations has been
observed in the ExAC cohort.
Previously, genome wide association studies
(GWAS) of unrelated patients with sJIA did not re-
veal significant -log10 p values for the FAMIN locus
[9]. Therefore, variants within this gene do not seem
to play a role in patients suffering from the common
forms of sJIA. However, GWA studies can only detect
frequent variants. Cases of juvenile arthritis caused by
FAMIN mutations have to be distinguished from the
common forms of (s)JIA. Since these cases are not re-
stricted to systemic forms and are not ‘idiopathic’
they should be referred to as monogenic juvenile arth-
ritis. The severity of the phenotypes in terms of diffi-
cult disease control underlines the clinical need to
separate these entities from common forms of sJIA.
Whether the phenotype of monogenic juvenile arth-
ritis is restricted to familial cases has to be analyzed
in larger cohort studies.
Large GWAS, including several thousands of patients
with infectious and autoimmune diseases give evidence
to a major role of FAMIN in the inflammatory response:
in patients with leprosy an association of the common
variant p.Ile254Val (rs37641479) located within FAMIN
was found and the gene activity is discussed as a host-
resistance factor in leprosy [13–16]. The same variant
was found in cohorts with increased susceptibility to
Crohn’s disease pointing to a common host response
pathway in leprosy and Crohn’s disease [17, 18]. Further-
more, the ‘familial sJIA variant’ p.Cys284Arg was de-
tected in a family with early-onset Crohn’s disease [19].
Crohn’s disease and infections share some phenotypical
aspects of JIA, e.g. the occurrence of arthritis and the
systemic inflammatory reaction. Current pathophysio-
logical concepts of JIA furthermore indicate an import-
ant role of a dysregulation within pathogen-sensing
mechanisms, e.g. the inflammasomes. Together with the
observation of similar genetic alterations this suggests
that pathophysiological pathways are shared in these
three diseases. Moreover, the now known function of
FAMIN and the described variants causing different
forms of JIA these underlines that the found variants are
not simply in tight linkage disequilibrium with a causa-
tive variant but are truly causative.
When introduced into a murine model, the variants
p.Cys284Arg, associated with ‘familial sJIA’ and early on-
set Crohn’s disease, as well as the SNP p.Ile254Val asso-
ciated with increased susceptibility to Crohn’s disease
and leprosy, suppressed the observed metabolic changes
as measured by means of extracellular acidification rate
and oxygen-consumption rate [12]. Thus, an ex vivo
assay exists to determine the gene-dose effect on meta-
bolic cell function.
The altered metabolic cell function observed ex vivo,
reflects the severity of clinical phenotypes. In this re-
spect, p.Ile254Val led to rather mild cellular changes
with increased susceptibility to leprosy and Crohn’s dis-
ease, whereas the p.Cys284Arg variant caused stronger
metabolic alterations resulting in a more severe pheno-
type with early-onset Crohn’s disease or ‘familial sJIA’, re-
spectively. This genotype-phenotype correlation is
furthermore supported as the novel frameshift mutation
p.Thr276fs reported here is of higher predicted patho-
genicity than the missense variant p.Cys284Arg. This hy-
pothesis is supported by the fact, that the stop codon at
amino acid position 276 is located upstream of 284 and
therefore affects the consecutive N-terminal amino acids
288 to 430.
After BMT, the child (II-3) does not show any signs of
arthritis. Given the fact, that FAMIN is closely linked to
the inflammatory function of macrophages, this observa-
tion underlines the pathophysiological importance of
this cell type in sJIA.
Taken together, we present a family with closely re-
lated parents with two children suffering of severe forms
of monogenic juvenile arthritis caused by homozygous
variants within FAMIN. In line with the previously de-
scribed cases of FAMIN-related familial systemic and
polyarticular JIA, the reported association with other in-
flammatory and infectious diseases, respectively, as well
as the currently published pathophysiological role of
FAMIN, these cases add evidence for a causative role of
the alterations in the development of these inflammatory
phenotypes.
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